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Abstract
Background
Continuous deep sedation until death is a highly debated medical practice, particularly
regarding its potential to hasten death and its proper use in end-of-life care. A thorough
analysis of important trends in this practice is needed to identify potentially problematic
developments. This study aims to examine trends in the prevalence and practice character-
istics of continuous deep sedation until death in Flanders, Belgium between 2007 and 2013,
and to study variation on physicians’ degree of palliative training.
Methods
Population-based death certificate study in 2007 and 2013 in Flanders, Belgium. Reporting
physicians received questionnaires about medical practices preceding the patient’s death.
Patient characteristics, clinical characteristics (drugs used, duration, artificial nutrition/
hydration, intention and consent), and palliative care training of attending physician were
recorded. We posed the following question regarding continuous deep sedation: ‘Was the
patient continuously and deeply sedated or kept in a coma until death by the use of one or
more drugs’.
Results
After the initial rise of continuous deep sedation to 14.5% in 2007 (95%CI 13.1%-15.9%), its
use decreased to 12.0% in 2013 (95%CI 10.9%-13.2%). Compared with 2007, in 2013 opi-
oids were less often used as sole drug and the decision to use continuous deep sedation
was more often preceded by patient request. Compared to non-experts, palliative care
experts more often used benzodiazepines and less often opioids, withheld artificial nutri-
tion/hydration more often and performed sedation more often after a request from or with
the consent of the patient or family.
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Conclusion
Worldwide, this study is the first to show a decrease in the prevalence of continuous deep
sedation. Despite positive changes in performance and decision-making towards more
compliance with due care requirements, there is still room for improvement in the use of rec-
ommended drugs and in the involvement of patients and relatives in the decision-making
process.
Introduction
Physicians caring for patients with an advanced disease are often confronted with important
but complex end-of-life decisions that affect the patient’s manner of dying [1]. When termi-
nally ill patients experience unbearable symptoms that cannot be alleviated by conventional
treatments, administering drugs to induce unconsciousness can be an option of last resort to
relieve suffering [2,3]. Large-scale population-based surveys monitoring end-of-life practices
on a nationwide scale have so far consistently shown an increased use of continuous deep seda-
tion until death. In Flanders, the overall prevalence of this practice increased considerably
between 2001 and 2007, rising from 8.2% to 14.5% of all deaths [4,5]. In the Netherlands, stud-
ies found that the prevalence of continuous deep sedation increased from 8.2% in 2005 to
12.3% of all deaths in 2010 [1,6,7].
Continuous deep sedation until death remains a highly debated medical practice, particu-
larly regarding its potential to hasten death and its proper use in end-of-life care [8–10]. In
light of the clinical and ethical challenges associated with the practice, several guidelines and
recommendations have been developed around the world. In Flanders the Federation for Palli-
ative Care implemented a guideline in 2010 [11], describing conditions under which sedation
at the end of life should be performed [12–14]. Like guidelines in many other countries, it rec-
ommends that continuous deep sedation until death should only be performed close to death
for unbearable and refractory symptoms without intent to hasten death [15,16]. Benzodiaze-
pines, titrated proportionally to alleviate the symptoms, are the drug of first choice and the
administration of artificial nutrition or hydration is not encouraged unless the benefits out-
weigh the harm [4,12].
Empirical studies indicate that there is considerable variation regarding this medical prac-
tice and that physicians are not always well acquainted with the conditions under which con-
tinuous deep sedation until death should be performed [17]. The effectiveness of guidelines,
being non-committal and non-mandatory, in changing physicians’ attitudes, knowledge and
practices have been called into question [18]. In the Netherlands, where the Royal Dutch Medi-
cal Association issued a clinical guideline in 2005 and a revised guideline in 2009 [19], studies
have suggested that guidelines can certainly lead to considerable practice improvements in
accordance with guideline requirements [20]. Some of the results even suggest better compli-
ance with the guidelines when physicians had more palliative care expertise [21]. This might
also be the case in Belgium after the introduction of the Flemish guideline by the Federation for
Palliative Care in 2010. This study describes recent developments in the prevalence and charac-
teristics of continuous deep sedation until death in Belgium between 2007 and 2013 and studies
variation in performance and decision-making depending on the degree of palliative care train-
ing of the physician.
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Methods
Study design
We conducted a population-based death certificate survey identical to surveys in 1998, 2001
and 2007, based on a representative sample of deaths in Flanders, Belgium. This region has
approximately six million inhabitants and 60.000 deaths annually [4,22]. To limit the time
between the certification of death and the inclusion in the study, a stratified random sample of
deaths in 2013 was drawn weekly from the Flemish Agency for Care and Health, the central
administration authority for processing death certificates. From our previous studies [5,23,24]
we know that end-of-life decisions occur more frequently among patients with a certain cause
of death. We therefore adopted disproportionate sampling of deaths to include more patients
with a cause of death known to have a higher likelihood of one or more end-of-life decisions.
All deaths from January 1st until June 30th 2013 of Belgian residents aged one year or older
were assigned to one of three strata, based on underlying cause of death as indicated on the
death certificate and the estimated corresponding likelihood of an end-of-life decision. Sam-
pling fractions for each stratum increased with this likelihood [23]. In the first stratum, all
deaths for which euthanasia was mentioned on the death certificate were sampled. In the sec-
ond stratum, one third of all cancer deaths were sampled. In the third stratum, one in six deaths
resulting from any other cause was sampled. This resulted in a sample of 6.871 deaths, about
21% of all deaths in the studied period.
Within two months of the death, the certifying physician received a four-page questionnaire
with an introductory letter containing patient identifiers. The physician was requested to com-
plete the questionnaire by consulting the patient’s medical file. If the certifying physician was
not the treating physician, the questionnaire was passed on to the treating physician. One phy-
sician could receive participation requests for up to five decedents, with at most three remind-
ers per death; every sixth case was excluded and another death was sampled from the same
stratum and the same place of death. To guarantee absolute anonymity for participating physi-
cians, a lawyer served as an intermediary between responding physicians, researchers and the
Flemish Agency for Care and Health, ensuring that completed questionnaires could never be
linked to a particular patient or physician. Patients were deceased, and consent was not
required. Physicians’ participation was regarded as implicit consent, which was noted in the
accompanying letter introducing the study. After data collection a one-page questionnaire was
mailed to all non-responding physicians inquiring about reasons for not participating. The
mailing and anonymity procedures were approved by the Ethical Review Board of the Univer-
sity Hospital of the Vrije Universiteit Brussel, the Belgian National Disciplinary Board of Physi-
cians and the Belgian Privacy Commission.
Questionnaire
The repeatedly validated questionnaire on end-of-life decision-making first asked whether
death had been sudden and unexpected. The rest of the questionnaire was to be completed
only if death had not been sudden and unexpected. The following question, identical to that
used in 2001 [22,25] and 2007 [23], was posed regarding continuous deep sedation:Was the
patient continuously and deeply sedated or kept in a coma until death by the use of one or more
drugs?. We used a descriptive definition of the practice (continuous deep sedation until death)
rather than a term (palliative or terminal sedation) to avoid interpretation differences among
respondents. The physician’s degree of palliative training is coded if he/she reported that they
(1) had not had palliative care training; (2) had only had some palliative care training in the
basic curriculum; (3) had followed continued palliative care training or (4) worked as part of a
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palliative care team (palliative care experts). Demographic and clinical patient data were
obtained from the death certificate data and linked anonymously after data collection.
Statistical analysis
The response sample was corrected for disproportionate stratification by weighting each stra-
tum to make the proportion in the response sample identical to the proportion in all deaths
and adjusted to be representative of all deaths in the first half of 2013 in terms of age, sex, mari-
tal status, province of death, cause of death and place of death (adjustments needed for prov-
ince and place of death). After this weighting procedure there were no significant differences
between response sample and all deaths in any of these variables. Final weights varied between
0.11 and 1.90. This procedure was also used in previous survey years. Bivariate cross-tabula-
tions and multivariable logistic regression models were calculated to compare prevalence and
characteristics of continuous deep sedation between 2007 and 2013. Multivariable models
incorporated the most important confounders: sex, age, cause of death and place of death. All
statistical analyses were calculated with complex samples functions in SPSS version 22.0.
Results
Of the 6.871 deaths sampled, questionnaires were returned for 3.751 cases. From the non-
response analysis we found that response was impossible for 683 deaths (e.g. because the physi-
cian did not have access to the patient’s medical file or the patient could not be identified).
These cases were removed from the sample. Response rate was therefore 60.6% (3.751/6.188
eligible cases) compared with 58.4% in 2007. Analysis of non-response questionnaires revealed
lack of time as the most quoted reason for non-participation. Between 2007 and 2013 there was
an increased proportion of decedents aged 80+ from 50.0% to 57.1% and deaths in nursing
homes rose from 22.6% in 2007 to 26.9% in 2013 (data not shown). Cancer consistently
accounted for around one in four deaths.
The overall prevalence of continuous deep sedation decreased significantly from 14.5%
(95%Cl 13.1–15.9) to 12.0% (95%Cl 10.9–13.2, p = 0.007) (Table 1). The decreasing trend is
visible in nearly all patient groups, but is statistically significant only in women (from 15.4%
[95%Cl 13.5–17.6] in 2007 to 11.8% [95%Cl 10.3–13.6] in 2013), in decedents of 80 years or
older (from 11.1% [95%Cl 9.4–13.0] to 8.9% [95%Cl 7.6–10.3]), in persons with primary diag-
noses other than cancer (12.9%[95%Cl 11.2–14.8] to 10.4% [95%Cl 7.6–10.3]), in decedents
with a high school or college/university degree (from 18.5% [95%Cl 15.3–22.2] to 13.0% [95%
Cl 10.6–15.8]), among widowed decedents (11.8% [95%Cl 9.9–14.0] to 8.4% [7.0–10.1]) and
among those living in care homes (9.4% [95%Cl 7.4–11.8] to 6.6% [95%Cl 5.2–8.4]). The
decrease remained significant after simultaneously controlling for relevant confounding factors
for the total prevalence of continuous sedation (p = 0.037), among women (p = 0.017), in
patients with a high school or college/university degree (p = 0.019), among widow(er)s
(p = 0.022) and those dying in care homes (p = 0.035).
Benzodiazepines and opioids were the most frequently used drug combination in 2007 and
2013, and opioids were less often used in 2013 as sole drug (Table 2). Compared to 2007, seda-
tion in 2013 was more often performed with propofol (23.1% vs 11%). The duration of sedation
was relatively shorter in 2013 compared with 2007, with a higher proportion of continuous
deep sedations lasting less than 24 hours (35.8% vs 24.4%). Though artificial nutrition or
hydration was less often administered until death in 2013 (38.3% vs 42.5% in 2007), multivari-
able analysis showed this was due the increased proportion of decedents aged 80 and over, for
whom artificial nutrition or hydration is less likely (not in table). Sedation was more often per-
formed after a request from the patient in 2013 (15.3%) than in 2007 (9.7%). The lacking of
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patient or family consent mainly occurred in the hospital setting (89.4% vs 93.4% in 2007) and
in persons with primary diagnoses other than cancer (78.6% vs 81.5% in 2007) such as cardio-
vascular diseases (35.1% vs 37.6% in 2007) (not in table). No significant differences were found
regarding the intention of hastening death between 2007 and 2013. In 2013, the life-shortening
effect of sedation was explicitly intended or co-intended in 17.9% of cases.
The performance and decision-making characteristics of continuous deep sedation until
death in 2013 differed according to the degree of the physician’s palliative care expertise
(Table 3). The use of benzodiazepines increased with palliative care expertise, whereas the use
of opioids and propofol decreased (p<0.001). Those with training or expertise also withheld
artificial nutrition or hydration more often (p<0.001) and sedation by palliative care experts
Table 1. Prevalence of continuous deep sedation until death (CDS) and baseline characteristics of patients receiving CDS between 2007 and
2013a,b.
Number of cases Weighted percentages Biv. P-value
2007 2013 2007 2013
N = 3623 N = 3751 % (95%Cl) % (95%Cl)
Total CDS 561 438 14.5 (13.1–15.9) 12.0 (10.9–13.2) 0.007
Sex
Male 1875 1920 13.5 (11.8–15.6) 12.2 (10.6–13,9) 0.275
Female 1748 1826 15.4 (13.5–17.6) 11.8 (10.3–13.6) 0.006
Age (in years)
1–64 741 632 19.3 (16.1–23.0) 16.5 (13.5–20.0) 0.245
65–79 1267 1100 17.1 (9.5–14.0) 16.0 (13.7–18.6) 0.540
80+ 1615 2014 11.1 (9.4–13.0) 8.9 (7.6–10.3) 0.050
Cause of death
Cancer 2018 1470 18.4 (16.6–20.3) 16.6 (14.7–18.8) 0.222
Non-cancer 1605 2258 12.9 (11.2–14.8) 10.4 (9.1–11.9) 0.032
Education
Primary school 1196 923 13.3 (11,2–15,8) 10.2 (8.2–12.6) 0.054
High school (not
graduated)
692 639 13.7 (10.8–17.3) 12.5 (10.0–15.7) 0.598
High school/college 726 778 18.5 (15.3–22.2) 13.0 (10.6–15.8) 0.010
Marital status
Unmarried 357 372 12.0 (8.6–16.5) 8.7 (6.1–12.3) 0.192
Married 1798 1618 17.5 (15.4–19.9) 15.9 (14.0–18.0) 0.296
Widow(er) 1252 1445 11.8 (9.9–14.0) 8.4 (7.0–10.1) 0.008
Divorced 214 305 13.0 (8.6–19.0) 14.7 (10.8–19.6) 0.629
Setting c
At home 1265 1133 9.8 (8.3–11.6) 8.7 (7.2–10.4) 0.336
Hospital d 1382 1447 19.5 (17.2–22.0) 17.0 (15.0–19.1) 0.120
Care Home 850 1038 9.4 (7.4–11.8) 6.6 (5.2–8.4) 0.037
a Figures are weighted percentages of all deaths and 95% conﬁdence intervals. Figures in bold denote statistically signiﬁcant differences between 2007
and 2013.
b After controlling for the most important confounders (age, sex, cause of death and place of death) differences in the following groups between 2007 and
2013 remained signiﬁcant: total CDS, female, high school/college, Widow(er) and care home. The direction of bivariate associations did not change in
multivariate analysis.
c Other place of death not included in table: 13 cases in 2007 and 12 cases in 2013.
d In 2013, we could distinguish different departments within the hospitals. In 2013, continuous sedation until death within the hospital was more often used
in an intensive care unit (50.5%, 95%CI 43.8–57.6) than in a palliative care unit (23.9%, 95%CI 16.7–32.9) (p<0.001).
doi:10.1371/journal.pone.0158188.t001
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was more often preceded by a request of the patient (p = 0.025) and less often without any
request or consent of the patient or his or her family (p = 0.001). All significant bivariate results
were also found significant after controlling for the most important confounders: sex, age,
cause of death and place of death. The direction of bivariate associations did not change in
multivariate analysis.
Discussion
Our robust population-based study found that after the initial rise of continuous deep sedation
until death between 2001 and 2007 from 8.2% to 14.5%, its use decreased to 12.0% in 2013. The
decrease particularly occurred in women, widowed people, those dying in nursing homes and
Table 2. Characteristics of performing continuous deep sedation until death in 2007 and 2013a b.
N Total CDS Chi2 P-Value c,d
2007 2013 2007 2013
N = 561 N = 438 % %
Drugs administered <0.001
Only benzodiazepines 72 52 11.2 10.5
Benzodiazepines and opioids (+other drugs) 239 213 42.4 46.2
Propofol (+benzodiazepines/opioids/other drugs) 32 73 11.0 23.1
Only opioids 167 79 30.7 16.7
Other combinations 24 16 4.7 3.5
Duration of sedation <0.001
0–24 hours 125 153 24.4 35.8
1–7 days 321 247 61.7 54.5
1–2 weeks 58 21 11.2 6.0
More than 2 weeks 12 12 2.7 3.7
Artiﬁcial nutrition and hydration 0.038
Administered until death 159 129 42.5 38.3
Withdrawn during sedation 43 49 9.4 12.5
withheld 347 258 48.1 49.2
Request or consent 0.095
Request by patient 71 83 9.7 15.3
No request, but consent of patient 135 100 20.3 19.5
No request or consent of patient, but request by family 78 60 11.8 13.8
No request or consent of patient, but consent of family 186 131 38.4 35.2
No request or consent of patient or family 74 54 19.8 16.2
Intention of hastening death 0.329
No intention 124 99 32.4 29.2
Taking into account possible hastening of death 280 236 51.2 52.9
Co-intention 77 64 12.9 15.2
Explicit intention 18 14 1.1 2.7
a Figures are weighted column percentages. Percentages may not always amount to 100% because of rounding. Figures in bold denote statistically
signiﬁcant differences between 2007 and 2013.
b Missing cases: drugs administered (26 in 2007 and 5 in 2013), duration of sedation (45 in 2007 and 5 in 2013), artiﬁcial nutrition and hydration (12 in
2007 and 2 in 2013), request or consent (17 in 2007 and 10 in 2013) and intention of hastening death (62 in 2007 and 25 in 2013).
c After controlling for the most important confounders (age and place of death), differences in ‘artiﬁcial nutrition and hydration’ can be attributed to the
increased proportion of decedents aged 80 and over.
d P-values were calculated with Fisher’s exact test (in StatXact version 6).
doi:10.1371/journal.pone.0158188.t002
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the more highly educated. In 2013, compared with 2007 opioids were less often used as sole
drug and the decision to use continuous deep sedation was more often preceded by an explicit
patient request. Compared to non-experts, palliative care experts more often used benzodiaze-
pines and less often opioids, withheld artificial nutrition or hydration more often and more
often performed sedation after a request or with the consent of the patient or family.
So far, large-scale population-based surveys estimating the prevalence or development of
continuous deep sedation until death have consistently found an increase in its use
[1,4,5,22,26,27]. This study is the first to show a decrease in the use of continuous deep
Table 3. Performance and decision-making characteristics of continuous deep sedation until death in 2013 according to the degree of physicians’
palliative care (PC) expertisea,b,c.
No PC training PC training in the
basic curriculum
Continuing PC
training courses
Specialist Biv. P-Value d
N = 126 N = 109 N = 138 N = 63
Drugs administered <0.001
Only benzodiazepines 7.8 4.2 14 22.0
Benzodiazepines and opioids (+other drugs) 32.9 52.5 52.1 55.0
Propofol (+benzodiazepines/opioids/other drugs) 36.2 30.1 11.7 0
Only opioids 19.0 12.8 19.4 13.2
Other combinations 4.1 0.4 2.8 9.8
Duration of sedation 0.524
0–24 hours 33.3 38.4 36.5 35.9
1–7 days 51.6 55.5 54.4 61.4
1–2 weeks 9.6 3.4 6.1 2.8
More than 2 weeks 5.6 2.7 2.9 0
Artiﬁcial nutrition and hydration <0.001
Administered until death 48.6 49.6 25.7 17.1
Withdrawn during sedation 8.8 21.0 12.4 5.0
withheld 42.6 29.4 61.9 77.9
Request or consent 0.009
Request by patient 8.2 17.5 17.2 23.7
No request, but consent of patient 21.1 15.2 21.1 21.7
No request or consent of patient, but request by
family
11.5 12.4 16.9 16.1
No request or consent of patient, but consent of
family
34.8 34.7 38.8 31.1
No request or consent of patient or family 24.5 20.1 6.1 7.3
Intention of hastening death 0.107
No intention 36.5 33.3 24.0 13.3
Taking into account possible hastening of death 43.0 51.0 59.9 65.9
Co-intention 17.2 13.2 13.7 18.4
Explicit intention 3.3 2.4 2.4 2.4
a Figures are weighted column percentages. Percentages may not always amount to 100% because of rounding. Figures in bold denote statistically
signiﬁcant differences according to the degree of physicians’ palliative care expertise.
b Missing cases: drugs administered (5), duration of sedation (5), artiﬁcial nutrition and hydration (2), request or consent (10) and intention of hastening
death (25).
c All signiﬁcant bivariate results were also found signiﬁcant after controlling for the most important confounders: sex, age, cause of death and place of
death. The direction of bivariate associations did not change in multivariate analysis.
d P-values were calculated with Fisher’s exact test (in StatXact version 6).
doi:10.1371/journal.pone.0158188.t003
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sedation, with the prevalence dropping from 14.5% in 2007 to 12.0% in 2013. This decrease
could be attributable to Flemish physicians’ and other health care workers’ increased training
and experience in palliative care and in controlling distressing symptoms without the need to
use continuous deep sedation as an option of last resort. The decrease of continuous sedation
may also be related to the specific Belgian context of end-of-life decision-making where eutha-
nasia—defined as medical administration of life-ending drugs at the patient’s explicit request—
is legal under a number of conditions [28]. A recent Belgian study found increasing numbers
of euthanasia requests and granting rates between 2007 and 2013 [5]. This increase mainly
took place in the same subgroups in which the present study found the use of continuous deep
sedation to have substantially decreased during the same period [29]. There is evidence that in
Flemish clinical practice euthanasia and continuous deep sedation are often discussed as alter-
native options, the choice between them depending on the preferences of patients and others
involved [16,30,31]. It thus seems that the option of euthanasia is now chosen more often, due
possibly to an increasing acceptance of euthanasia by patients, as well as by physicians and care
institutions who in the past may more often have converted euthanasia requests into continu-
ous deep sedation [32,33]. Other possible explanations for the decrease in continuous deep
sedation are that ongoing ethical and clinical insights may have led to the view that the practice
of continuous sedation is not ‘normal’ end-of-life treatment holding back some physicians
from using it [13,16,34], or that increased attention to advance care planning, when patients
are still capable of participating in end-of-life decisions, has reduced instances in which contin-
uous sedation is performed as a crisis intervention in the absence of clear preferences or direc-
tives [35,36].
Our study found a number of striking changes in the performance of and decision-making
preceding continuous deep sedation: in 2013, more sedations were carried out using a combi-
nation of benzodiazepines and opioids, with opioids less frequently used as sole drug than in
2007 and sedation was more often performed after a patient’s request, even though patient or
family consent was still often lacking. In general, our study observed a number of developments
in the practice of continuous deep sedation between 2007 and 2013 which are favourable in
light of the recommendations described in the existing guidelines, including the 2010 Flemish
guideline. This would corroborate research from the Netherlands showing that the practices of
care providers had been positively influenced by the introduction of the Dutch guideline, first
published in 2005, though the Dutch practice seems to fit more closely with the recommenda-
tions of the Dutch guideline than does the Flemish practice with the Flemish guideline
[19,20,37]. There is still no insight into whether and to what extent guidelines, being non-man-
datory, are applied in Flanders, Belgium. The fact that the Flemish guideline is issued by the
Federation responsible for palliative care, rather than by a medical or health care association,
can be expected to limit their spread. Our study suggests that there still is room for further
improvement, particularly in the use of recommended drugs, seeking consent and not intend-
ing to hasten death. This raises the question whether guidelines alone can ensure sound prac-
tice. Too much emphasis on guidelines may encourage routinisation and could obscure the
vital importance of case-by-case-based decision-making [38]. Following the proposed safe-
guards of Quill et al [39] for ethically complex practices such as continuous deep sedation (i.e.
obtaining informed consent, ensuring diagnostic and prognostic clarity, obtaining an indepen-
dent second opinion and documenting and reviewing the processes to ensure accountability)
some are therefore calling for the mandatory consultation of palliative care experts or even
mandatory reporting of continuous deep sedation as is the case for regulated euthanasia in Bel-
gium [34,40,41]. However, in this study, palliative care training was associated with end-of-life
sedation practices more congruent with recommendations. Therefore, a feasible alternative to
mandatory consultation or reporting could be to encourage and enhance physician training in
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palliative care. Dutch research has found that the choice of recommended drugs for continuous
deep sedation until death was associated with the use of guidelines and with the care team
including, or consulting with a palliative care expert [1,21]. This suggests that palliative care
training may thus improve a physician’s skills in performing end-of-life sedation as well as
encourage them to adopt a multidisciplinary approach and consult end-of-life experts for this
practice.
Although our study uses a robust population-based sampling method, a number of study
limitations have to be taken into account. While high response rates were achieved, we cannot
exclude some degree of non-response bias. However, analysis of non-response questionnaires
revealed lack of time as the most quoted reason for non-participation. Our study only provides
information from the physician’s perspective, and does not permit in-depth case analysis.
Recall bias may also have influenced results, although attempts were made to limit this by
ensuring that the physician received the questionnaire no later than eight weeks after their
patient’s death. Sensitivity of survey topics may introduce untruthful or socially desirable
reporting, but this is unlikely in our study given the explicit guarantee of anonymity and the
fact that physicians were well acquainted with the survey. To minimize possible differences in
the perception of sedation among the respondents we provided them with a descriptive defini-
tion of the practice (continuous deep sedation until death). Most other studies use terms such
as palliative or terminal sedation, which can have various connotations. Furthermore, it is not
known when the palliative care training reported by the respondents took place, nor the extent
and content of the training.
Conclusions
The decreased use of continuous deep sedation until death in almost all patient groups may
suggest the development of a more critical approach and a more cautious attitude towards the
practice among Flemish physicians. The specific context of legal euthanasia in Belgium may
also play a role, and more research into the influence of different legal and cultural contexts on
performance of continuous deep sedation until death is recommended. Despite positive
changes in performance and decision-making towards more compliance with due care require-
ments, there is still room for improvement. Future studies should focus on whether quality
improvement initiatives like mandatory consultation and basic palliative care training would
improve the practice.
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